Assembly Biosciences vs Gossamer Bio
ASMB and GOSS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASMB and GOSS compare
Gossamer Bio is the larger company, worth 12 times as much as Assembly Biosciences ($5.4B against $433M).
Assembly Biosciences grew revenue faster over the last twelve months (125% versus 32.4% for Gossamer Bio).
Assembly Biosciences keeps more of each dollar of sales as profit, with a net margin of −0.06% compared with −235% at Gossamer Bio.
Assembly Biosciences scores higher on the StockData Score (12 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASMB | GOSS |
|---|---|---|
| Size and price | ||
| Market cap | $433M | $5.4B |
| Share price | $21.29 | $10.98 |
| Change, 1 year | −40.1% | −94.5% |
| Change, 5 years | −24.5% | −98.7% |
| Beta (5Y) | 1.01 | 2.34 |
| Employees | 73 | 161 |
| StockData Score | ||
| Total score | 12 (better) | 1 |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.8× (better) | 101× |
| P/B | 1.4× | – |
| FCF yield | −8.9% | −3.0% (better) |
| Fair value | $24.73 | – |
| Margin of safety | 13.9% | – |
| Growth | ||
| Revenue growth (TTM) | 125% (better) | 32.4% |
| Revenue growth, 5Y average | −1.8% | – |
| Profitability | ||
| Operating margin | −11.8% (better) | −312% |
| Net margin | −0.06% (better) | −235% |
| FCF margin | −51.5% (better) | −305% |
| Return on equity | −0.03% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −15.2× |
| Current ratio | 13.99 (better) | 0.53 |
| Altman Z-score | 8.00 (better) | −15.36 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.1% | 0.98% |
| Held by insiders | 29.3% | 2.8% |
| Insider net buying, 12 months | −$252K | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 21.1% | 0.28% |
Go deeper
- ASMB stock overview
- ASMB income statement
- ASMB valuation and score
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.